Stockreport

Insmed ENCORE Phase 3 Trial Hits Primary Endpoint; ARIKAYCE Drives Strong MAC Culture Conversion Gains [Yahoo! Finance]

Insmed Incorporated  (INSM) 
Last insmed incorporated earnings: 4/30 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.insmed.com
PDF Insmed (NASDAQ:INSM) reported top-line results from its phase III ENCORE trial evaluating ARIKAYCE in adults with non-cavitary lung disease and a newly diagnosed or rec [Read more]